Chronic lymphocytic leukaemia: When and how to treat
β Scribed by Rozman, Ciril ;Montserrat, Emilio
- Publisher
- Springer-Verlag
- Year
- 1989
- Weight
- 803 KB
- Volume
- 59
- Category
- Article
- ISSN
- 1432-0584
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Gangliosides were analysed by elaborated overpressured thin-layer chromatography (OPTLC) in 6 cell samples from 5 patients with chronic lymphocytic leukaemia (CLL) of Btell origin, and 4 individual lymphocyte preparations from normal blood donors. The principal difference in the ganglioside profile
Sequential cytogenetic studies were performed on a minimum of two and a maximum of nine occasions (mean 3.6) on the peripheral blood leucocytes of 112 patients with B-CLL. On initial cytogenetic analysis, 58 had a normal karyotype and 64 had a clonal abnormality. Karyotypic evolution occurred in 18
## Abstract Bβcell chronic lymphocytic leukaemia (BβCLL) is a heterogeneous disease with some patients having an indolent course never needs treatment, while others having rapidly progressive one requires intensive treatment. In recent decades, numerous prognostic markers, such as immunoglobulin va